CA2754352A1 - Postsynaptically targeted chemodenervation agents and their methods of use - Google Patents

Postsynaptically targeted chemodenervation agents and their methods of use Download PDF

Info

Publication number
CA2754352A1
CA2754352A1 CA2754352A CA2754352A CA2754352A1 CA 2754352 A1 CA2754352 A1 CA 2754352A1 CA 2754352 A CA2754352 A CA 2754352A CA 2754352 A CA2754352 A CA 2754352A CA 2754352 A1 CA2754352 A1 CA 2754352A1
Authority
CA
Canada
Prior art keywords
chemodenervation
polypeptide
alpha
neurotoxin
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2754352A
Other languages
English (en)
French (fr)
Inventor
Lars Erik Peters
Todd Lorenz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MYOCEPT Inc
Original Assignee
MYOCEPT Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MYOCEPT Inc filed Critical MYOCEPT Inc
Publication of CA2754352A1 publication Critical patent/CA2754352A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA2754352A 2008-02-19 2009-02-19 Postsynaptically targeted chemodenervation agents and their methods of use Abandoned CA2754352A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6634708P 2008-02-19 2008-02-19
US61/066,347 2008-02-19
PCT/US2009/034578 WO2009105585A2 (en) 2008-02-19 2009-02-19 Postsynaptically targeted chemodenervation agents and their methods of use

Publications (1)

Publication Number Publication Date
CA2754352A1 true CA2754352A1 (en) 2009-08-27

Family

ID=40986187

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2754352A Abandoned CA2754352A1 (en) 2008-02-19 2009-02-19 Postsynaptically targeted chemodenervation agents and their methods of use

Country Status (9)

Country Link
US (1) US9815875B2 (enExample)
EP (1) EP2250193B1 (enExample)
JP (1) JP2011523935A (enExample)
CN (1) CN102007142A (enExample)
AU (1) AU2009215436A1 (enExample)
CA (1) CA2754352A1 (enExample)
ES (1) ES2757648T3 (enExample)
IL (1) IL207631A0 (enExample)
WO (1) WO2009105585A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7259237B1 (en) 2006-12-29 2007-08-21 Miller Kent D Pan-antiviral peptides
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
KR20120093312A (ko) * 2009-10-30 2012-08-22 바이엘 헬스케어 엘엘씨 항체 모방체 스캐폴드
US9220743B2 (en) 2010-01-22 2015-12-29 Nuovo Biologics, Llc Pan-antiviral peptides for protein kinase inhibition
CN103145799B (zh) * 2013-02-18 2014-04-16 大连理工大学 一组具有促进经皮和跨膜渗透作用的多肽及其应用
CN104232653B (zh) * 2014-09-19 2017-04-05 中南大学湘雅医院 重组α‑银环蛇毒素αBtx的制备方法
JP2020518653A (ja) * 2017-02-07 2020-06-25 マイオセプト インコーポレイティド 局所製剤及び方法
CN110090296A (zh) * 2018-09-21 2019-08-06 祁展楷 一组与烟碱乙酰胆碱受体具有高度亲和力能快速起效的眼镜蛇神经毒素分子在镇痛上的应用
CN118561963A (zh) 2018-10-16 2024-08-30 格罗制药公司 烟碱乙酰胆碱受体肽拮抗剂芋螺毒素组合物及相关方法
AU2019408420B2 (en) * 2018-12-21 2025-04-17 Vib Vzw Fusion protein with a toxin and scaffold protein
EP3753568A1 (en) * 2019-06-21 2020-12-23 Fastox Pharma SA Composition modulating botulinum neurotoxin effect
CN110478473B (zh) * 2019-07-14 2025-08-12 江苏毫末医药生物科技有限公司 眼镜蛇神经毒素多肽对鸦片类药品痛觉过敏和耐受的抑制及对其镇痛的协同增效作用
EP4046648A4 (en) * 2019-10-11 2023-10-18 Qi, Zhankai Application of elapidae snake postsynaptic neurotoxin monomer molecule in treatment of alzheimer's disease
EP4093378A1 (en) * 2020-01-24 2022-11-30 W.L. Gore & Associates, Inc. Sustained-release matrices for adventitial or periadventitial neural ablation and uses thereof
CN111544571A (zh) * 2020-06-02 2020-08-18 沈喆景 眼镜蛇科蛇突触后神经毒素在治疗与炎性细胞因子过度表达相关疾病的应用
CN114409757B (zh) * 2022-01-26 2023-07-18 云南南诏药业有限公司 一种蛇毒神经毒素及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447356A (en) * 1981-04-17 1984-05-08 Olivera Baldomero M Conotoxins
FR2762009B1 (fr) * 1997-04-10 1999-06-04 Commissariat Energie Atomique Enzymes recombinantes purifiees a activite prolylpeptidasique, leur procede de preparation et leurs applications
IL143379A (en) * 2001-05-24 2013-11-28 Yissum Res Dev Co Oligonucleotide against human ache isoform r and its uses
US7964630B2 (en) 2004-11-02 2011-06-21 Dsm Ip Assets B.V. Topical application agents against mimic and age-related wrinkles
WO2007035474A2 (en) 2005-09-15 2007-03-29 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
US7659252B2 (en) * 2005-09-15 2010-02-09 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof

Also Published As

Publication number Publication date
JP2011523935A (ja) 2011-08-25
ES2757648T3 (es) 2020-04-29
AU2009215436A1 (en) 2009-08-27
IL207631A0 (en) 2010-12-30
EP2250193A2 (en) 2010-11-17
US20110118190A1 (en) 2011-05-19
EP2250193B1 (en) 2019-09-18
US9815875B2 (en) 2017-11-14
CN102007142A (zh) 2011-04-06
WO2009105585A3 (en) 2009-12-23
WO2009105585A2 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
US9815875B2 (en) Postsynaptically targeted chemodenervation agents and their methods of use
JP5341808B2 (ja) Ｃｎｓ治療用のプロテオグリカン分解変異体
KR102240347B1 (ko) 노화와 연관된 질환을 치료하기 위한 방법 및 조성물
EP1993589B1 (en) Treatments for neurological disorders
AU2013211846A1 (en) Growth differentiation factor 15 (GDF-15) polypeptides
CN109890411A (zh) 结核病组合物和治疗或预防结核病的方法
AU2006310577B2 (en) Use of SDF-1 for the treatment and/or prevention of neurological diseases
KR20140068148A (ko) 이질통, 통각과민증, 자발통 및 환상통의 치료
JP2007534746A (ja) 化学療法誘発性ニューロパシーの治療または予防のためのｉｌ−６
EP3010524A1 (en) Protamine in treatment of neuronal injuries
JP5048658B2 (ja) 神経性炎症性疾患の治療、及び／又は予防のためのｉｌ−１８ｂｐアイソフォームの使用
AT511913A2 (de) Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels
HK1123210A (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150219